Prepared: January 2026, Curated by Nelson Vergel
Key Finding: Evolocumab induces significant coronary plaque regression and stabilization but does not differentially affect coronary calcium accumulation compared to statin monotherapy. However, PCSK9 inhibitors may slow the rate of CAC...